Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: bacteriophage therapies - Pherecydes

Next Previous
X
Search
Drug Profile

Research programme: bacteriophage therapies - Pherecydes

Alternative Names: P. aeruginosa phage therapy - PHAXIAM Therapeutics; PP 1231; PP 2351; S. aureus phage therapy - PHAXIAM Therapeutics

Latest Information Update: 19 Apr 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherecydes Pharma
  • Developer PHAXIAM Therapeutics
  • Class Bacteriophages; Pseudomonas phages; Staphylococcus phages
  • Mechanism of Action Bacterial DNA modulators; Bacterial RNA modulators; Cell membrane modulators; Cell wall modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Bacterial endocarditis
  • Preclinical Klebsiella infections; Urinary tract infections
  • No development reported Bone and joint infections; Respiratory tract infections

Most Recent Events

  • 15 Apr 2024 Phase-I clinical trials in Bacterial endocarditis in France (IV)
  • 15 Apr 2024 PHAXIAM Therapeutics plans phase I trial in Endocarditis in Q4-2023
  • 19 Sep 2023 Preclinical trials in Klebsiella infections in France (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top